Ruxolitinib phosphate

{
  "id": "MLC-T-ONC-007521",
  "term": "Ruxolitinib phosphate",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with certain types of primary myelofibrosis (MF), post-polycythemia vera MF, post-essential thrombocythemia MF, or polycythemia vera, and adults and children aged 12 years and older with acute or chronic graft-versus-host disease. It is also being studied in the treatment of some types of cancer. Ruxolitinib phosphate blocks a protein called JAK, which may help keep abnormal blood cells or cancer cells from growing. It may also lower the body’s immune response. Ruxolitinib phosphate is a type of tyrosine kinase inhibitor. Also called Jakafi.",
    "The phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies."
  ],
  "synonyms": [
    "Jakafi",
    "INCB-18424 phosphate"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ruxolitinib-phosphate/"
}